Publication: The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: a Turkish Oncology Group Study
dc.contributor.coauthor | Ak, Naziye | |
dc.contributor.coauthor | Özkan, Berker | |
dc.contributor.coauthor | Yenigün, Mustafa B. | |
dc.contributor.coauthor | Yılmazbayhan, Dilek | |
dc.contributor.coauthor | Toker, Alper | |
dc.contributor.coauthor | Ferhatoğlu, Ferhat | |
dc.contributor.coauthor | Yaşar, Arzu | |
dc.contributor.coauthor | Sak, Serpil Dizbay | |
dc.contributor.coauthor | Kılıçkap, Sadettin | |
dc.contributor.coauthor | Önder, Sevgen | |
dc.contributor.coauthor | Dikmen, Erkan | |
dc.contributor.coauthor | Alan, Özkan | |
dc.contributor.coauthor | Yumuk, Perran F. | |
dc.contributor.coauthor | Bozkurtlar, Emine | |
dc.contributor.coauthor | Laçin, Tunç | |
dc.contributor.coauthor | Yıldızeli, Bedrettin | |
dc.contributor.coauthor | Özturk, Akın | |
dc.contributor.coauthor | Ürer, Nur | |
dc.contributor.coauthor | Oyan, Başak | |
dc.contributor.coauthor | Aydıner, Adnan | |
dc.contributor.coauthor | Demirkazık, Ahmet | |
dc.contributor.coauthor | Eralp, Yeşim | |
dc.contributor.coauthor | Kocatürk, Celalettin | |
dc.contributor.coauthor | Karapınar, Kemal | |
dc.contributor.kuauthor | Tanju, Serhan | |
dc.contributor.kuauthor | Dilege, Şükrü | |
dc.contributor.kuauthor | Erus, Suat | |
dc.contributor.kuauthor | Bulutay, Pınar | |
dc.contributor.kuauthor | Fırat, Pınar Arıkan | |
dc.contributor.kuauthor | Mandel, Nil Molinas | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.kuprofile | Teaching Faculty | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.yokid | 214690 | |
dc.contributor.yokid | 122573 | |
dc.contributor.yokid | 175565 | |
dc.contributor.yokid | 133565 | |
dc.contributor.yokid | 207545 | |
dc.contributor.yokid | 194197 | |
dc.date.accessioned | 2024-11-10T00:07:43Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Purpose: The benefit of adjuvant chemotherapy for tumors smaller than 4 cm is not clear. We aimed to evaluate the prognostic impact of adjuvant platin-based chemotherapy in high-risk stage I patients with non-small cell lung cancer (NSCLC). Methods: This cooperative group study included 232 NSCLC patients who underwent curative surgery for stage I disease with tumor size 2-4 cm. Results: Median age at presentation was 63 years (range 18-90). The mean tumor size was 29.6 +/- 7.3 mm. The frequency of patients with specified risk factors were: visceral pleural effusion (VPI): n: 82 (36.6%); lymphovascular invasion (LVI): n: 86 (39.1%); Grade 3: n: 48 (32.7%); Solid micropapillary pattern (SMP): n: 70 (48.3%). Adjuvant platin-based chemotherapy was administered to 51 patients. During a median follow-up period of 50.5 months 68 patients (29.3%) developed recurrence, 54 (23.3%) died from any cause and 38 (16.4%) of them died of lung cancer. Patients who received chemotherapy compared with the non-chemotherapy group had a longer 5-years relapse-free survival (RFS) (84.5 vs. 61.1%). Also on multivariate analysis, adjuvant chemotherapy was a significant independent prognostic factor for RFS. Conclusion: Adjuvant platin-based chemotherapy should be considered for patients with small tumors with adverse risk factors. | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 3 | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 26 | |
dc.identifier.doi | N/A | |
dc.identifier.eissn | 2241-6293 | |
dc.identifier.issn | 1107-0625 | |
dc.identifier.quartile | Q4 | |
dc.identifier.scopus | 2-s2.0-85109741732 | |
dc.identifier.uri | https://www.jbuon.com/archive/26-3-819.pdf | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/16834 | |
dc.identifier.wos | 668815400026 | |
dc.keywords | Adjuvant chemotherapy | |
dc.keywords | Lung cancer | |
dc.keywords | Oncology | |
dc.keywords | Lymphovascular invasion | |
dc.keywords | Solid-micropapillary pattern | |
dc.keywords | Platinum-based therapy | |
dc.language | English | |
dc.publisher | Imprimatur Publications | |
dc.source | Journal of Buon | |
dc.subject | Oncology | |
dc.title | The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: a Turkish Oncology Group Study | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.authorid | 0000-0002-2363-233X | |
local.contributor.authorid | 0000-0002-1071-5291 | |
local.contributor.authorid | 0000-0002-6162-3266 | |
local.contributor.authorid | 0000-0001-5497-1513 | |
local.contributor.authorid | 0000-0001-8340-2678 | |
local.contributor.authorid | 0000-0002-8837-0756 | |
local.contributor.kuauthor | Tanju, Serhan | |
local.contributor.kuauthor | Dilege, Şükrü | |
local.contributor.kuauthor | Erus, Suat | |
local.contributor.kuauthor | Bulutay, Pınar | |
local.contributor.kuauthor | Fırat, Pınar Arıkan | |
local.contributor.kuauthor | Mandel, Nil Molinas |